mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity—Does it matter?
- 10 May 2023
- journal article
- research article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 75, 104761
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Administration of COVID-19 vaccines in immunocompromised patientsInternational Immunopharmacology, 2021
- Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance studyThe Lancet Infectious Diseases, 2021
- Humoral response to SARS-CoV-2 COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapiesMultiple Sclerosis and Related Disorders, 2021
- mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2021
- Safety and efficacy of COVID-19 vaccines in multiple sclerosis patientsJournal of Neuroimmunology, 2021
- Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222)Frontiers in Immunology, 2021
- Mini-Review Discussing the Reliability and Efficiency of COVID-19 VaccinesDiagnostics, 2021
- Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapiesTherapeutic Advances in Neurological Disorders, 2021
- Effect of ocrelizumab on vaccine responses in patients with multiple sclerosisNeurology, 2020
- Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosisNeurology, 2015